
FIG. 1




*Statistics: ** p<0.01(Newman-Keuls) versus all other groups at 48h-delay*

Donepezil 3mg/kg p.o.

API 3mg/kg p.o.

FIG. 2



*Statistics versus Veh-scopolamine: *** p=0.0001(ANOVA) *p=0.02 two-tailed Dunnett*

FIG. 3



worsening
improvement
ADAS-Cog total score change from baseline
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
W4
W12
W24
FUP
Visit
Placebo
API 0.5mg
API 2mg
API 5mg
*p = 0.048

FIG. 4



worsening
ADCS-ADL global score change from baseline
1.0
0.5
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
-3.5
-4.0
-4.5
-5.0
-5.5
-6.0
-6.5
-7.0
-7.5
Placebo
API 0.5mg
API 2mg
API 5mg
* p=0.02
W12
W24
FUP
Placebo
API 0.5mg
API 2mg
API 5mg

FIG. 5



Placebo
API 0.5mg
API 2mg
API 5mg
Power of attention (msec) change from baseline
260
240
220
200
180
160
140
120
100
80
60
40
20
0
-20
-40
-60
-80
W8
W24

FIG. 6





AES-I Change from baseline
6
5
4
3
2
1
0
-1
-2
BL
12W
24W
FUP
* p=0.04 vs placebo
Placebo
API 0.5mg
API 2mg
API 5mg

FIG. 7



** p=0.01 vs placebo (Pb)

FIG. 8


Episodic memory Change from baseline
20
15
10
5
0
-5
-10
-15
-20
p = 0.02 vs placebo
Placebo
API 0.5mg
API 2mg
API 5mg
Baseline
8 weeks
24 weeks
Follow-up